Updates are available Correction dated 2019-04-16
Click to view Correction: https://doi.org/10.1186/s13075-019-1887-x
-
Authors
Tanaka, Yoshiya http://orcid.org/0000-0002-0807-7139
Wada, Kazuteru
Takahashi, Yoshinori
Hagino, Owen
van Hoogstraten, Hubert
Graham, Neil M. H.
Kameda, Hideto
-
Funding
Funding for this research was provided by:
Sanofi K.K.
- License Information
-
More Information
Article History
Received: 25 July 2018
Accepted: 28 February 2019
First Online: 20 March 2019
Change Date: 16 April 2019
Change Type: Correction
Change Details: Following publication of the original article [1], the authors reported an error in Table 2.
Ethics approval and consent to participate
: The protocol was approved by the appropriate independent ethics committees/institutional review boards for each of the 95 participating sites, and each patient gave written informed consent. The study was conducted in compliance with recommendations of The International Conference on Harmonisation Guidelines for Good Clinical Practice, and the Declaration of Helsinki.
: Not applicable.
: YTan has received speaking fees from Daiichi Sankyo, Inc., Astellas Pharma Inc., Pfizer Inc., Mitsubishi Tanabe Pharma, Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., YL Biologics Ltd., Eli Lilly and Company, Sanofi K.K., Janssen Pharmaceutical K.K., and UCB Japan Co. Ltd., and has received research grants from Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company, Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., Astellas Pharma Inc., AbbVie G.K., MSD K.K., Daiichi Sankyo, Inc., Pfizer Inc., Kyowa Kirin, Inc., Eisai Co., Ltd., and Ono Pharmaceutical Co., Ltd. KW, YTak, OH, and HvH are employees of Sanofi and may hold stock and/or stock options in the company. NMHG is an employee of Regeneron and may hold stock and/or stock options in the company. HK has received consulting fees, speaking fees, and/or honoraria from AbbVie G.K., Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma, Novartis Pharma K.K., and Sanofi K.K., and has received research grants from AbbVie G.K., Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Mitsubishi Tanabe Pharma, Novartis Pharma K.K., and Sanofi K.K.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
